Odiparcil
Mucopolysaccharidosis Type VI (MPS VI)
Phase IIActive (Partnered with Hepalys Pharma)
Key Facts
Indication
Mucopolysaccharidosis Type VI (MPS VI)
Phase
Phase II
Status
Active (Partnered with Hepalys Pharma)
Company
About Inventiva
Inventiva's mission is to develop innovative, oral small molecule therapies for significant unmet medical needs in fibrotic, lysosomal, and oncologic diseases. Its key achievement is the advancement of lanifibranor, a novel pan-PPAR agonist, into a pivotal Phase III trial for MASH/NASH, supported by strong Phase IIb data and regulatory recognition. The company's strategy is built on its proprietary drug discovery platform, strategic partnerships for development and commercialization, and a focus on oral administration to maximize patient compliance and commercial potential.
View full company profile